Skip to main content
Menu

Posts tagged with "Uncategorized"

  • Oxford/AZ Vaccine Efficacy Data

    As of this morning, we have a first look at the Oxford/AstraZeneca vaccine’s efficacy in clinical trials via press releases from both organizations. The number in the headlines says about 70% efficacy, but there’s more to the story. Here’s the landscape so far: we have results from Pfizer and from Moderna, both of them developing… Read More
  • That Kodak Deal

    Many people have been wondering what’s going on with the announcement by the Trump administration that Kodak has been contracted to produce pharmaceutical APIs here in the US. Let’s line up some of the public statements about all this first, and then take a closer look. Here’s the press release from Kodak after signing a “L… Read More
  • Vaccine Derangement

    I’m working on a new vaccine roundup post for tomorrow – it’s been a couple of weeks, and there’s a lot of news to catch up on. But first off, a comment on vaccines in general. As the prospect of these become more real in the public mind, I’m noticing more and more anti-vaccine takes, from… Read More
  • Thoughts on Antibody Persistence and the Pandemic

    The fundamental challenge of dealing with this pandemic is uncertainty. There are just too many important things that we don’t know – and what’s more, they aren’t easy to find out, either. We’ve seen that with the waves of optimism and pessimism about various therapies, just to pick one. As everyone has been learning … Read More
  • Another Set of Coronavirus Vaccine Candidates

    I surveyed the coronavirus vaccine landscape in this post, and then detailed some of the larger efforts in the field here (several updates have been added to that one since its initial posting). Now it’s time to look at several programs that aren’t in either of those, but still have plenty of serious science behind… Read More
  • Good News on the Coronavirus-Angiotensin Connection

    Let’s use some news this morning as an example of how things go in clinical research. You’ll remember that earlier in the epidemic there was a sudden scare about angiotensin-targeting medications (ACE inhibitors and angiotensin receptor blockers, two very common modes of hypertension therapy). This came from the realization that the cor… Read More
  • More Small Molecule Clinical Data Against Covid-19, As of April 16

    There are several clinical trial updates for today – some that have reported data, and two that are apparently never going to report at all. I refer to trials of Gilead’s remdesivir in China, one for moderate cases and one for severe ones, both of which were updated yesterday to “suspended” on ClinicalTrials.gov. That took… Read More
  • More Therapeutic Ideas for the Coronavirus: Too Much Inflammation?

    So today I’d like to talk about some of the other anti-coronativirus possibilities that I haven’t gone into yet – these posts will never make a comprehensive list, but at least I can cover some of the more interesting ideas, I hope. Interleukin-6 is an interesting story. This preprint from German researchers presents some evidence… Read More
  • Known Drugs Being Tried Against the Coronavirus: Runner-Up Candidates

    Everyone’s heard plenty about chloroquine, azithromycin, remdesivir and other front-running ideas for anti-coronovirus therapies. Today I wanted to focus on some compounds that haven’t gotten as much attention but which have been proposed from more than one place as possibilities. Some of these have shown up in the comments to past post… Read More
  • Clinical Trials

    Adaptive Trials

    There are a lot of clinical trial designs out there. But one thing that a lot of them have in common is that they are designed right from the start to run under certain set conditions and to enroll a set number of people (or at least to meet certain thresholds before that enrollment is… Read More